Skip to main content

Table 1 Parameters comparison between the sham and dyslipidemia groups

From: Atorvastatin combined with poly-unsaturated fatty acid confers better improvement of dyslipidemia and endothelium function

Variables Sham (n = 10) Control (n = 10) Atorvastatin (n = 10) PUFA (n = 10) Combined (n = 10)
At initial
TG (mmol/L) 1.08 ± 0.11 1.03 ± 0.12 1.04 ± 0.10 1.06 ± 0.11 1.04 ± 0.12
TC (mmol/L) 3.82 ± 0.21 3.80 ± 0.16 3.81 ± 0.17 3.78 ± 0.16 3.78 ± 0.14
LDL-C (mmol/L) 2.03 ± 0.15 1.98 ± 0.12 2.01 ± 0.12 2.00 ± 0.12 2.01 ± 0.13
HDL-C (mmol/L) 0.92 ± 0.06 0.92 ± 0.05 0.93 ± 0.07 0.91 ± 0.03 0.90 ± 0.07
NO (μmol/L) 12.24 ± 1.23 12.09 ± 1.16 12.13 ± 1.17 12.20 ± 1.09 12.12 ± 1.18
CRP (mg/L) 2.08 ± 0.36 2.11 ± 0.23 2.04 ± 0.29 2.10 ± 0.19 2.11 ± 0.24
sVCAM (μg/mL) 3.52 ± 0.26 3.57 ± 0.33 3.49 ± 0.20 3.50 ± 0.30 3.52 ± 0.35
sICAM (μg/mL) 0.43 ± 0.06 0.41 ± 0.03 0.44 ± 0.05 0.43 ± 0.05 0.42 ± 0.05
MDA (nmol/L) 0.86 ± 0.05 0.89 ± 0.05 0.82 ± 0.04 0.86 ± 0.07 0.85 ± 0.04
1 week of atherogenic diet treatment
TG (mmol/L) 1.10 ± 0.12* 1.23 ± 0.18 1.24 ± 0.13 1.20 ± 0.09 1.22 ± 0.06
TC (mmol/L) 3.85 ± 0.20* 4.35 ± 0.13 4.40 ± 0.17 4.41 ± 0.12 4.38 ± 0.11
LDL-C (mmol/L) 2.06 ± 0.12* 2.35 ± 0.26 2.32 ± 0.32 2.30 ± 0.26 2.30 ± 0.21
HDL-C (mmol/L) 0.93 ± 0.06 0.90 ± 0.06 0.90 ± 0.07 0.91 ± 0.03 0.92 ± 0.05
NO (μmol/L) 12.18 ± 1.09* 9.26 ± 1.02 9.23 ± 1.06 9.25 ± 1.02 9.20 ± 1.07
CRP (mg/L) 2.07 ± 0.32* 4.63 ± 0.43 4.61 ± 0.34 4.58 ± 0.30 4.60 ± 0.26
sVCAM (μg/mL) 3.50 ± 0.25* 4.95 ± 0.42 4.92 ± 0.36 4.92 ± 0.18 4.93 ± 0.27
sICAM (μg/mL) 0.44 ± 0.05* 0.58 ± 0.07 0.56 ± 0.06 0.63 ± 0.08 0.65 ± 0.06
MDA (nmol/L) 0.88 ± 0.04* 1.09 ± 0.06 1.05 ± 0.04 1.07 ± 0.04 1.07 ± 0.06
  1. Denote: *p < 0.05 versus other groups.